VA
WHWK

Verdad Advisers’s Whitehawk Therapeutics WHWK Stock Holding History

Verdad Advisers’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$398K Buy
+115,484
New +$362K 0.45% 80

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Verdad Advisers's WHWK Position: Q1 2026 in Review

Verdad Advisers opened a new position in Whitehawk Therapeutics (WHWK) in Q1 2026: 115,484 shares worth $398K. The stake represents 0.45% of the portfolio and ranks #80 among its holdings.

62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Verdad Advisers held 115,484 shares of Whitehawk Therapeutics worth $398K as of Q1 2026.
  • Whitehawk Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Whitehawk Therapeutics made up 0.45% of Verdad Advisers's portfolio in Q1 2026, its #80 holding.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.